Corrigendum to "Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study" [eBioMedicine 83 (2022) 104208]

Affiliations

• ¹ Clinical & Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
• ² David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
• ³ Benaroya Research Institute, Seattle, WA, USA.
• ⁴ University of California San Francisco School of Medicine, San Francisco, CA, USA.
• ⁵ Drexel University/Tower Health Hospital, Philadelphia, PA, USA.
• ⁶ University of Arizona, Tucson, AZ, USA.
• ⁷ Boston Clinical Site: Precision Vaccines Program, Boston Children's Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
• ⁸ Yale School of Medicine, Yale School of Public Health, New Haven, CT, USA.
• ⁹ Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• ¹⁰ Stanford University, Palo Alto, CA, USA.
• ¹¹ Oregon Health Sciences University, Portland, OR, USA.
• ¹² Oklahoma University Health Sciences Center, Oklahoma, OK, USA.
• ¹³ University of Florida, Gainesville and University of South Florida, Tampa, FL, USA.
• ¹⁴ Baylor College of Medicine, The Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey, Houston, TX, USA.
• ¹⁵ The University of Texas at Austin, Austin, TX, USA.
• ¹⁶ Case Western Reserve University, Cleveland, OH, USA.
• ¹⁷ La Jolla Institute for Immunology, La Jolla, CA, USA.
• ¹⁸ National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA.
• ¹⁹ Emory University, Atlanta, GA, USA. Electronic address: nroupha@emory.edu.